Search

Your search keyword '"Kibengo, Freddie"' showing total 131 results

Search Constraints

Start Over You searched for: Author "Kibengo, Freddie" Remove constraint Author: "Kibengo, Freddie"
131 results on '"Kibengo, Freddie"'

Search Results

1. Optimising DTwP-containing vaccine infant immunisation schedules (OptImms) — a protocol for two parallel, open-label, randomised controlled trials

3. Dose finding study for on-demand HIV pre-exposure prophylaxis for insertive sex in sub-Saharan Africa: results from the CHAPS open label randomised controlled trial

4. Acceptability and applicability of biometric iris scanning for the identification and follow up of highly mobile research participants living in fishing communities along the shores of Lake Victoria in Kenya, Tanzania, and Uganda

5. Rapid, early, and potent Spike-directed IgG, IgM, and IgA distinguish asymptomatic from mildly symptomatic COVID-19 in Uganda, with IgG persisting for 28 months

7. Utility of Different Adherence Measures for PrEP: Patterns and Incremental Value

8. Baseline C-reactive Protein as a Risk Factor for Cryptococcal Meningitis and Death in HIV-associated Cryptococcal Antigenemia With CrAg Titer as an Effect Modifier.

9. Safety and Broad Immunogenicity of HIVconsvX Conserved Mosaic Candidate T-Cell Vaccines Vectored by ChAdOx1 and MVA in HIV-CORE 006: A Double-Blind, Randomized, Placebo-Controlled Phase 1 Trial in Healthy Adults Living Without HIV-1 in Eastern and Southern Africa

10. Dose finding study for on-demand HIV pre-exposure prophylaxis for insertive sex in sub-Saharan Africa: results from the CHAPS open label randomised controlled trial

11. Safety and tolerability of adjunctive linezolid with high or standard dose rifampin for the treatment of adults with HIV-associated tuberculous meningitis in Uganda: preliminary findings from the ALTER trial (S25.003)

13. Pre-pandemic SARS-CoV-2-specific IFN-γ and antibody responses were low in Ugandan samples and significantly reduced in HIV-positive specimens

14. Social networks, mobility, and HIV risk among women in the fishing communities of Lake Victoria

15. Characterization of Near Full-Length Transmitted/Founder HIV-1 Subtype D and A/D Recombinant Genomes in a Heterosexual Ugandan Population (2006–2011)

17. Acceptability and Applicability of Biometric Iris Scanning for the Identification and Follow Up of Highly Mobile Research Participants Living in Fishing Communities Along the Shores of Lake Victoria in Kenya, Tanzania, and Uganda

18. Short Communication: Validation of the Asante HIV-1 Rapid Recency Assay for Detection of Recent HIV-1 Infections in Uganda

19. Adjunctive Dexamethasone in HIV-Associated Cryptococcal Meningitis

20. Knowledge, Attitudes, and Practices Regarding COVID-19 among Healthcare Workers in Uganda: A Cross-Sectional Survey

21. Willingness to participate in COVID-19 vaccine trials; a survey among a population of healthcare workers in Uganda

22. Quality of life and associated factors among HIV positive patients after completion of treatment for Cryptococcal meningitis

23. Determinants of two-year mortality among HIV positive patients with Cryptococcal meningitis initiating standard antifungal treatment with or without adjunctive dexamethasone in Uganda

24. Cohort Profile: IAVI’s HIV epidemiology and early infection cohort studies in Africa to support vaccine discovery

25. Quality of life and associated factors among HIV positive patients after completion of treatment for Cryptococcal meningitis

26. Pervasive and non-random recombination in near full-length HIV genomes from Uganda

27. PS-003: EVIDENCE-INFORMED POLICY MAKING: CHALLENGES AND OPPORTUNITIES

28. Population Pharmacokinetic Model and Meta-analysis of Outcomes of Amphotericin B Deoxycholate Use in Adults with Cryptococcal Meningitis

29. Control of the HIV-1 Load Varies by Viral Subtype in a Large Cohort of African Adults With Incident HIV-1 Infection

31. Using verbal autopsy to assess the prevalence of HIV infection among deaths in the ART period in rural Uganda: a prospective cohort study, 2006-2008

32. Correction for Stott et al., “Population Pharmacokinetics and Cerebrospinal Fluid Penetration of Fluconazole in Adults with Cryptococcal Meningitis”

33. Correction for Stott et al., “Population Pharmacokinetic Model and Meta-analysis of Outcomes of Amphotericin B Deoxycholate Use in Adults with Cryptococcal Meningitis”

34. THE RESULTS OF THE EV06 DNA-PROTEIN COMBINATION TRIAL AND PLANS FOR GREAT, AN EDCTP2-FUNDED CONSERVED-MOSAIC EPITOPE HIV VACCINE TRIAL

35. Understanding mobility and sexual risk behaviour among women in fishing communities of Lake Victoria in East Africa: a qualitative study.

36. Population Pharmacokinetics and Cerebrospinal Fluid Penetration of Fluconazole in Adults with Cryptococcal Meningitis

37. Do Intracerebral Cytokine Responses Explain the Harmful Effects of Dexamethasone in Human Immunodeficiency Virus–associated Cryptococcal Meningitis?

38. Population Pharmacokinetic Model and Meta-analysis of Outcomes of Amphotericin B Deoxycholate Use in Adults with Cryptococcal Meningitis

41. Do Intracerebral Cytokine Responses Explain the Harmful Effects of Dexamethasone in Human Immunodeficiency Virus–associated Cryptococcal Meningitis?

42. Comparing the Novel Method of Assessing PrEP Adherence/Exposure Using Hair Samples to Other Pharmacologic and Traditional Measures

43. CryptoDex: A randomised, double-blind, placebo-controlled phase III trial of adjunctive dexamethasone in HIV-infected adults with cryptococcal meningitis: study protocol for a randomised control trial

45. Trends of Reported HIV Sexual Risk Behaviour and HIV Incidence among Fisherfolk in Uganda Receiving Clinic-based Routine HIV Counseling and Testing

47. Willingness to participate in HIV vaccine efficacy trials among high risk men and women from fishing communities along Lake Victoria in Uganda

48. Safety, Adherence and Acceptability of Intermittent Tenofovir/Emtricitabine as HIV Pre-Exposure Prophylaxis (PrEP) among HIV-Uninfected Ugandan Volunteers Living in HIV-Serodiscordant Relationships: A Randomized, Clinical Trial

50. Participation in Clinical Research Could Modify Background Risk for Trial Outcome Measures.

Catalog

Books, media, physical & digital resources